Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma
Background. This study aims to explore the efficacy of tumor-infiltrating lymphocytes (TIL) along with interferon-α (IFN-α) to treat stage III malignant melanoma (MM) patients in China. Methods. Between May 2010 and October 2014, 77 patients of stage III MM who underwent surgery were collected in th...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2017/1092507 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467331075375104 |
|---|---|
| author | Wei Li Linping Xu Yaomei Wang Lingdi Zhao Daniel B. Kellner Quanli Gao |
| author_facet | Wei Li Linping Xu Yaomei Wang Lingdi Zhao Daniel B. Kellner Quanli Gao |
| author_sort | Wei Li |
| collection | DOAJ |
| description | Background. This study aims to explore the efficacy of tumor-infiltrating lymphocytes (TIL) along with interferon-α (IFN-α) to treat stage III malignant melanoma (MM) patients in China. Methods. Between May 2010 and October 2014, 77 patients of stage III MM who underwent surgery were collected in this study. These patients were divided into two groups: patients who received TIL + IFN-α ± RetroNectin-activated cytokine-induced killer cells (R-CIK) in Arm 1 (n=27) and IFN-α ± R-CIK in Arm 2 (n=50) as adjuvant therapy. The primary endpoints were disease-free survival (DFS) time and DFS rates measured at time points of 1, 2, and 3 years. The secondary endpoints were overall survival (OS) rates measured at time points of 1, 2, 3, and 5 years as well as OS as evaluated by Kaplan-Meier. Results. Our results indicated that the median DFS and OS in Arm 1 were significantly better than those in Arm 2. The data also demonstrated that DFS rate and OS rates in Arm 1 were significantly better than those in Arm 2 at all measured time points. Conclusion. Patients who undergo surgical excision of stage III MM appear to enjoy prolonged DFS and OS when treated with TIL + IFN-α compared to IFN-α alone. |
| format | Article |
| id | doaj-art-de9c9fe11d33474aae271015a2be22c4 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-de9c9fe11d33474aae271015a2be22c42025-08-20T03:26:16ZengWileyJournal of Immunology Research2314-88612314-71562017-01-01201710.1155/2017/10925071092507Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant MelanomaWei Li0Linping Xu1Yaomei Wang2Lingdi Zhao3Daniel B. Kellner4Quanli Gao5Department of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaDepartment of Research and Foreign Affairs, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaSchool of Life Sciences, Zhengzhou University, Zhengzhou, Henan 450001, ChinaDepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaDepartment of Medicine, Weill Cornell Medical College, New York, NY 10065, USADepartment of Immunotherapy, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, ChinaBackground. This study aims to explore the efficacy of tumor-infiltrating lymphocytes (TIL) along with interferon-α (IFN-α) to treat stage III malignant melanoma (MM) patients in China. Methods. Between May 2010 and October 2014, 77 patients of stage III MM who underwent surgery were collected in this study. These patients were divided into two groups: patients who received TIL + IFN-α ± RetroNectin-activated cytokine-induced killer cells (R-CIK) in Arm 1 (n=27) and IFN-α ± R-CIK in Arm 2 (n=50) as adjuvant therapy. The primary endpoints were disease-free survival (DFS) time and DFS rates measured at time points of 1, 2, and 3 years. The secondary endpoints were overall survival (OS) rates measured at time points of 1, 2, 3, and 5 years as well as OS as evaluated by Kaplan-Meier. Results. Our results indicated that the median DFS and OS in Arm 1 were significantly better than those in Arm 2. The data also demonstrated that DFS rate and OS rates in Arm 1 were significantly better than those in Arm 2 at all measured time points. Conclusion. Patients who undergo surgical excision of stage III MM appear to enjoy prolonged DFS and OS when treated with TIL + IFN-α compared to IFN-α alone.http://dx.doi.org/10.1155/2017/1092507 |
| spellingShingle | Wei Li Linping Xu Yaomei Wang Lingdi Zhao Daniel B. Kellner Quanli Gao Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma Journal of Immunology Research |
| title | Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma |
| title_full | Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma |
| title_fullStr | Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma |
| title_full_unstemmed | Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma |
| title_short | Efficacy of Tumor-Infiltrating Lymphocytes Combined with IFN-α in Chinese Resected Stage III Malignant Melanoma |
| title_sort | efficacy of tumor infiltrating lymphocytes combined with ifn α in chinese resected stage iii malignant melanoma |
| url | http://dx.doi.org/10.1155/2017/1092507 |
| work_keys_str_mv | AT weili efficacyoftumorinfiltratinglymphocytescombinedwithifnainchineseresectedstageiiimalignantmelanoma AT linpingxu efficacyoftumorinfiltratinglymphocytescombinedwithifnainchineseresectedstageiiimalignantmelanoma AT yaomeiwang efficacyoftumorinfiltratinglymphocytescombinedwithifnainchineseresectedstageiiimalignantmelanoma AT lingdizhao efficacyoftumorinfiltratinglymphocytescombinedwithifnainchineseresectedstageiiimalignantmelanoma AT danielbkellner efficacyoftumorinfiltratinglymphocytescombinedwithifnainchineseresectedstageiiimalignantmelanoma AT quanligao efficacyoftumorinfiltratinglymphocytescombinedwithifnainchineseresectedstageiiimalignantmelanoma |